^
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
sintilimab Sensitive: A1 - Approval
Innovent Biologics Press Release - 6 days (New A1)
|
sintilimab Sensitive: A1 - Approval
Innovent Biologics Press Release - 6 days - (New A1)
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
erlotinib Sensitive: B - Late Trials
|
erlotinib Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
NTRK3 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK3 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK1 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
EGFR mutation
|
Esophageal Squamous Cell Carcinoma
|
EGFR mutation
|
Esophageal Squamous Cell Carcinoma
|
afatinib Sensitive: C1 - Off-label
|
afatinib Sensitive: C1 - Off-label
|
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
|
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
Z650 Sensitive: C2 – Inclusion Criteria
|
Z650 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AV-203 Sensitive: C3 – Early Trials
|
AV-203 Sensitive: C3 – Early Trials
|
NDRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
NDRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
SGK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
SGK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
AFAP1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AFAP1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
FP Resistant: C3 – Early Trials
|
FP Resistant: C3 – Early Trials
|
TLR signature
|
Esophageal Squamous Cell Carcinoma
|
TLR signature
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
NDRG1-H
|
Esophageal Squamous Cell Carcinoma
|
NDRG1-H
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DKN-01 Sensitive: C3 – Early Trials
|
DKN-01 Sensitive: C3 – Early Trials
|
NFKB1 expression
|
Esophageal Squamous Cell Carcinoma
|
NFKB1 expression
|
Esophageal Squamous Cell Carcinoma
|
rivoceranib Sensitive: C3 – Early Trials
|
rivoceranib Sensitive: C3 – Early Trials
|
KDR expression
|
Esophageal Squamous Cell Carcinoma
|
KDR expression
|
Esophageal Squamous Cell Carcinoma
|
rivoceranib Sensitive: C3 – Early Trials
|
rivoceranib Sensitive: C3 – Early Trials
|
PD-L1 overexpression + CCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression + CCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 underexpression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
TTN D7145H
|
Esophageal Squamous Cell Carcinoma
|
TTN D7145H
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Sensitive: C3 – Early Trials
|
cisplatin Sensitive: C3 – Early Trials
|
MYH4 Q1210fs
|
Esophageal Squamous Cell Carcinoma
|
MYH4 Q1210fs
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Sensitive: C3 – Early Trials
|
cisplatin Sensitive: C3 – Early Trials
|
MRE11A underexpression
|
Esophageal Squamous Cell Carcinoma
|
MRE11A underexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
UBQLN4 overexpression
|
Esophageal Squamous Cell Carcinoma
|
UBQLN4 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
TP53 mutation
|
Esophageal Squamous Cell Carcinoma
|
TP53 mutation
|
Esophageal Squamous Cell Carcinoma
|
SCT200 Sensitive: C3 – Early Trials
|
SCT200 Sensitive: C3 – Early Trials
|
CD44 overexpression + CD24 underexpression
|
Esophageal Squamous Cell Carcinoma
|
CD44 overexpression + CD24 underexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
CD73 underexpression
|
Esophageal Squamous Cell Carcinoma
|
CD73 underexpression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
CD73 underexpression
|
Esophageal Squamous Cell Carcinoma
|
CD73 underexpression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
CD276 overexpression
|
Esophageal Squamous Cell Carcinoma
|
CD276 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DS-7300 Sensitive: C3 – Early Trials
|
DS-7300 Sensitive: C3 – Early Trials
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
Z650 Sensitive: C3 – Early Trials
|
Z650 Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
CXCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
|
CXCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
CCL19 underexpression
|
Esophageal Squamous Cell Carcinoma
|
CCL19 underexpression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
UMODL1 underexpression
|
Esophageal Squamous Cell Carcinoma
|
UMODL1 underexpression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
IFNG-L
|
Esophageal Squamous Cell Carcinoma
|
IFNG-L
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
LAMP3-L
|
Esophageal Squamous Cell Carcinoma
|
LAMP3-L
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
LGALS1-L
|
Esophageal Squamous Cell Carcinoma
|
LGALS1-L
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Esophageal Squamous Cell Carcinoma
|
BRCA1 mutation
|
Esophageal Squamous Cell Carcinoma
|
FOLFOX Sensitive: C4 – Case Studies
|
FOLFOX Sensitive: C4 – Case Studies
|
CDK14 overexpression
|
Esophageal Squamous Cell Carcinoma
|
CDK14 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
MACC1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
MACC1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
PARP1 expression
|
Esophageal Squamous Cell Carcinoma
|
PARP1 expression
|
Esophageal Squamous Cell Carcinoma
|
anlotinib Sensitive: D – Preclinical
|
anlotinib Sensitive: D – Preclinical
|
TP53 mutation
|
Esophageal Squamous Cell Carcinoma
|
TP53 mutation
|
Esophageal Squamous Cell Carcinoma
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
CD31 expression
|
Esophageal Squamous Cell Carcinoma
|
CD31 expression
|
Esophageal Squamous Cell Carcinoma
|
anlotinib Sensitive: D – Preclinical
|
anlotinib Sensitive: D – Preclinical
|
BAX expression
|
Esophageal Squamous Cell Carcinoma
|
BAX expression
|
Esophageal Squamous Cell Carcinoma
|
anlotinib Sensitive: D – Preclinical
|
anlotinib Sensitive: D – Preclinical
|
SOX9 overexpression
|
Esophageal Squamous Cell Carcinoma
|
SOX9 overexpression
|
Esophageal Squamous Cell Carcinoma
|
nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical
|
nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
nimotuzumab Sensitive: D – Preclinical
|
nimotuzumab Sensitive: D – Preclinical
|
LYPD3 expression
|
Esophageal Squamous Cell Carcinoma
|
LYPD3 expression
|
Esophageal Squamous Cell Carcinoma
|
BAY1129980 Sensitive: D – Preclinical
|
BAY1129980 Sensitive: D – Preclinical
|
PER2 underexpression
|
Esophageal Squamous Cell Carcinoma
|
PER2 underexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin Sensitive: D – Preclinical
|
cisplatin Sensitive: D – Preclinical
|
HSPA6 expression
|
Esophageal Squamous Cell Carcinoma
|
HSPA6 expression
|
Esophageal Squamous Cell Carcinoma
|
metformin Sensitive: D – Preclinical
|
metformin Sensitive: D – Preclinical
|
